Comparative study of efficacy and safety of Administering 4mg once daily and 2mg twice daily of silodosin in patients with benign prostatic hyperplasia.

Trial Profile

Comparative study of efficacy and safety of Administering 4mg once daily and 2mg twice daily of silodosin in patients with benign prostatic hyperplasia.

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2009

At a glance

  • Drugs Silodosin (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Aug 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top